BMY Bristol-Myers Squibb Company

Bristol-Myers Squibb to Hold Investor Event to Discuss AACR Highlights

NEW YORK NEW YORK--(BUSINESS WIRE)--

Bristol-Myers Squibb Company (NYSE: BMY) will hold an investor event on Monday, April 16, 2018 at 6:00 p.m. EDT (5:00 p.m. CDT) to discuss data presented at the Annual Meeting of the American Association for Cancer Research (AACR) in Chicago. Company executives will provide an overview of data presented from the company’s oncology portfolio, and address questions from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the event at investor.bms.com. Materials related to the event will be available at the same website prior to the event. A replay of the event will be available and can be accessed at investor.bms.com.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

EN
02/04/2018

Underlying

BMYBristol-Myers Squibb Company

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bristol-Myers Squibb Company

BMY BRISTOL-MYERS SQUIBB COMPANY
11/26/25 November 26, 2025 1 EN
EUR 156.17
BMY Bristol-Myers S...

Bristol-Myers Squibb Company: Update to credit analysis

Our credit view of this issuer reflects its large scale and solid presence in the global pharmaceutical market, against its significant patent expirations.

BMY BRISTOL-MYERS SQUIBB COMPANY
11/25/25 November 25, 2025 1 EN
BMY Bristol-Myers S...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Bristol-Myers Squibb Company and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 19 November 2025 in which we reassessed the appropriateness of the ratings in ...

BMY BRISTOL-MYERS SQUIBB COMPANY
11/22/25 November 22, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.38
SNYN SANOFI S.A. ADS
NOVA Novo Nordisk A/... ... (+11)

Vermilion Compass: Weekly Equity Strategy

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...

SNYN SANOFI S.A. ADS
NOVA NOVO NORDISK A/S ADS
MRK MERCK & CO. INC.
LLY ELI LILLY AND COMPANY
JNJ JOHNSON & JOHNSON
BMY BRISTOL-MYERS SQUIBB COMPANY
NVS.. NOVARTIS AG ADS
ABBV ABBVIE INC.
BAYA BAYER AG ADS
AZN ASTRAZENECA PLC ADS
GSK GSK PLC
11/19/25 November 19, 2025 1 EN
Gary Brode
  • Gary Brode
LLY ELI LILLY AND COMPANY
BMY BRISTOL-MYERS SQUIBB COMPANY
PFE PFIZER INC.
10/06/25 October 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch